Research by scientists at the University of Bath is challenging claims that nanoparticles in medicated and cosmetic creams are able to transport and deliver active ingredients deep inside the skin. The study discovered that even the tiniest of nanoparticles did not penetrate the skin's surface.
Watch out, acne. Doctors soon may have a new weapon against zits: A harmless virus living on our skin that naturally seeks out and kills the bacteria that cause pimples. In the new findings, scientists looked at two little microbes that share a big name: Propionibacterium acnes , a bacterium thriving in our pores that can trigger acne, and P. acnes phages, a family of viruses that live on human skin.
U.K.-led scientists have made a discovery about snake venom that could lead to the development of new drugs to treat a range of life-threatening conditions. The researchers have discovered that the toxins that make snake and lizard venom deadly can evolve back into completely harmless molecules, raising the possibility that they could be developed into drugs.
Designed to improve the way businesses manage the scientific innovation lifecycle, the new Accelrys Process Management and Compliance Suite unifies Accelrys Inc.’s lifecycle management software offerings, covering the ground between product development and process execution. It is geared to help companies bring products to market faster and at a lower cost, while meeting critical quality and regulatory compliance objectives.
EMD Millipore and iPS Academia Japan Inc. (AJ) announced a global licensing agreement for AJ's induced pluripotent stem (iPS) cell patent portfolio. The non-exclusive agreement provides EMD Millipore the opportunity to continue to develop and ultimately commercialize iPS cells for research applications.
It's not a magic trick and it's not sleight of hand—scientists really are using levitation to improve the drug development process, eventually yielding more effective pharmaceuticals with fewer side effects. Scientists at Argonne National Laboratory have discovered a way to use sound waves to levitate individual droplets of solutions containing different pharmaceuticals.
According to data from a 2008 Business R&D and Innovation Survey by the National Science Foundation, businesses perform the lion's share of their R&D activity in just a small number of geographic areas, particularly the San Jose-San Francisco-Oakland area and the New York-Newark-Bridgeport area.
Time-consuming, expensive, and often intrusive, clinical trials are nevertheless a necessity. Researchers at the University of Tennessee Space Institute in Tullahoma have developed an invention that makes clinical trials more efficient. Called "digital Eye Bank," the computer software eye modeling program can take data from eyes of patients' and build it into models from the commercial optics program to be used for researchers' virtual clinical trials.
In a new study, University of Missouri medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer and added a special cluster of three elements: boron, carbon, and hydrogen. This structure, called a carborane, has multiplied the binding force of the drug. Clinical could start within two years.
A nanoparticle developed at Rice University and tested in collaboration with Baylor College of Medicine may bring great benefits to the emergency treatment of brain-injury victims, even those with mild injuries. Combined polyethylene glycol-hydrophilic carbon clusters (PEG-HCC), already being tested to enhance cancer treatment, are also adept antioxidants. In animal studies, injections of PEG-HCC during initial treatment after an injury helped restore balance to the brain's vascular system.
As the medical community continues to make positive strides in personalized cancer therapy, scientists know some dead ends are unavoidable. Drugs that target specific genes in cancerous cells are effective, but not all proteins are targetable. In fact, it has been estimated that as few as 10% to 15% of human proteins are potentially targetable by drugs. For this reason, Georgia Institute of Technology researchers are focusing on ways to fight cancer by attacking defective genes before they are able to make proteins.
One of the most daunting challenges facing pharmaceutical scientists today are "undruggable proteins"—the approximately 80% of proteins involved in human disease that do not interact with current drugs. Yale University researchers have identified a novel way to design drugs for these previously inaccessible proteins.
iBio Inc. and GE Healthcare announced a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010.
Yale University Cancer Center scientists have developed a new class of proteins that inhibit HIV infection in cell cultures and may open the way to new strategies for treating and preventing infection by the virus that causes AIDS.
A mysterious protein produced by a wide spectrum of living things is crucial in regulating the immune response to the most common form of pneumonia, a new Yale University School of Medicine study shows.
Two Los Alamos National Laboratory scientists are among the team recently funded to explore ways to create the precise immune factors needed for effective vaccines against HIV. The Duke University-led consortium will largely concentrate on inducing broadly neutralizing antibodies that can prevent HIV-1 infection, as well as on generating protective T-cell and innate immune system responses.
Researchers at Tufts University School of Engineering have discovered a way to maintain the potency of vaccines and other drugs—that otherwise require refrigeration—for months and possibly years at temperatures above 110 F, by stabilizing them in a silk protein made from silkworm cocoons.
A clinical trial of an Alzheimer's disease treatment developed at Massachusetts Institute of Technology has found that the nutrient cocktail can improve memory in patients with early Alzheimer's. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.
To foster the continued success of the biomanufacturing industry, North Carolina State University has joined forces with a French university to provide biomanufacturing training, education, and process services in the United States and Europe.
A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
At a recent weekend conference of more than 30,000 specialists, experts reported seeing a major escalation in the arms race against cancer. Several new advances, including “smart” drugs, immune system aids, and treatments based on genetic pathways, offer new hope for battling previously intractable diseases.
For 50 years scientists have been unsure how the bacteria that gives humans cholera manages to resist one of our basic innate immune responses. That mystery has now been solved, thanks to research from biologists at The University of Texas at Austin. The answers may help clear the way for a new class of antibiotics that don't directly shut down pathogenic bacteria, but instead disable their defenses so that our own immune systems can do the killing.
Getting a shot at the doctor's office may become less painful in the not-too-distant future. Massachusetts Institute of Technology researchers have engineered a device that delivers a tiny, high-pressure jet of medicine through the skin without the use of a hypodermic needle. The device can be programmed to deliver a range of doses to various depths—an improvement over similar jet-injection systems that are now commercially available.
The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale University School of Medicine researchers. The study counters perceptions that the drug approval process in the U.S. is especially slow.
Advisers to government health regulators late Thursday recommended that they approve sales of what would be the first new prescription weight-loss drug in the U.S. in more than a decade, despite concerns over cardiac risks.